- Home
- SUPN vs SPNT Comparison
SUPN vs SPNT Comparison
Compare SUPN & SPNT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | SUPN | SPNT |
|---|---|---|
| Founded | 2005 | 2011 |
| Country | United States | Bermuda |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Property-Casualty Insurers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.6B | 2.4B |
| IPO Year | 2012 | N/A |
Fundamental Metrics
Financial Performance| Metric | SUPN | SPNT |
|---|---|---|
| Price | $45.64 | $21.67 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 4 | 3 |
| Target Price | ★ $63.25 | $24.00 |
| AVG Volume (30 Days) | ★ 739.6K | 515.7K |
| Earning Date | 11-04-2025 | 10-30-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 1.45 |
| Revenue | $681,539,000.00 | ★ $2,859,100,000.00 |
| Revenue This Year | $8.32 | $0.89 |
| Revenue Next Year | $23.36 | $6.87 |
| P/E Ratio | ★ N/A | $14.83 |
| Revenue Growth | 4.54 | ★ 6.92 |
| 52 Week Low | $29.16 | $13.26 |
| 52 Week High | $57.65 | $21.86 |
Technical Indicators
Market Signals| Indicator | SUPN | SPNT |
|---|---|---|
| Relative Strength Index (RSI) | 45.90 | 67.25 |
| Support Level | $45.36 | $21.01 |
| Resistance Level | $47.26 | $21.86 |
| Average True Range (ATR) | 1.28 | 0.55 |
| MACD | 0.21 | 0.03 |
| Stochastic Oscillator | 44.79 | 89.62 |
Price Performance
Historical ComparisonAbout SUPN Supernus Pharmaceuticals Inc.
Supernus Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders. Its diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinson's Disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. The company's products include Trokendi XR, Oxtellar XR, Qelbree, APOKYN, XADAGO, MYOBLOC, GOCOVRI, and Osmolex ER.
About SPNT SiriusPoint Ltd.
SiriusPoint Ltd provides property and casualty reinsurance coverage to insurance and reinsurance companies in the United States, Canada, Bermuda, the United Kingdom, and Europe. The company operates through two operating segments: Reinsurance and Insurance & Services. The company's product portfolio consists of reinsurance contracts for property insurance including both residential and commercial properties, workers' compensation, personal automobile, businesses' general liability insurance, professional liability insurance to protect professional advisors and service providers, agriculture insurance, and mortgage insurance. The majority of the revenue is generated from its Insurance & Services segment.